The estimated Net Worth of Debra A Gordon is at least $61.9 Mille dollars as of 1 April 2016. Dr Gordon owns over 1,672 units of HTG Molecular Diagnostics Inc stock worth over $8,411 and over the last 10 years he sold HTGM stock worth over $53,528.
Dr has made over 7 trades of the HTG Molecular Diagnostics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 1,672 units of HTGM stock worth $4,832 on 1 April 2016.
The largest trade he's ever made was selling 5,535 units of HTG Molecular Diagnostics Inc stock on 10 March 2016 worth over $13,173. On average, Dr trades about 914 units every 9 days since 2015. As of 1 April 2016 he still owns at least 17,522 units of HTG Molecular Diagnostics Inc stock.
You can see the complete history of Dr Gordon stock trades at the bottom of the page.
Dr. Debra A. Gordon is the Sr. VP & Chief Legal Counsel at HTG Molecular Diagnostics Inc.
Dr Gordon is 61, he's been the Sr. VP & Chief Legal Counsel of HTG Molecular Diagnostics Inc since . There are 6 older and 9 younger executives at HTG Molecular Diagnostics Inc. The oldest executive at HTG Molecular Diagnostics Inc is Harry George, 71, who is the Independent Director.
Debra's mailing address filed with the SEC is C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON, AZ, 85706.
Over the last 10 years, insiders at HTG Molecular Diagnostics Inc have traded over $5,630,772 worth of HTG Molecular Diagnostics Inc stock and bought 1,019,150 units worth $14,128,765 . The most active insiders traders include Plc Gsk, Holdings A/S Novo e Laurence W Lytton. On average, HTG Molecular Diagnostics Inc executives and independent directors trade stock every 64 days with the average trade being worth of $28,039. The most recent stock trade was executed by Stephen Barat on 8 June 2023, trading 888 units of HTGM stock currently worth $710.
about htg molecular diagnostics: headquartered in tucson, arizona, htg's mission is to empower precision medicine at the local level. in 2013 the company commercialized its htg edge instrument platform and a portfolio of rna assays that leverage htg's proprietary nuclease protection chemistry. htg's product offerings have since expanded to include its htg edgeseq product line, which automates sample and targeted library preparation for next-generation sequencing. additional information is available at www.htgmolecular.com.
HTG Molecular Diagnostics Inc executives and other stock owners filed with the SEC include: